Vertex Pharmaceuticals Incorporated (LON:0QZU)
393.58
+10.85 (2.84%)
At close: Aug 13, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
8.98
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
74.81B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
Oxford Nanopore Technologies | 183.19M |
HUTCHMED (China) | 439.54M |
Vertex Pharmaceuticals News
- 1 day ago - Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet - Seeking Alpha
- 2 days ago - Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) - Seeking Alpha
- 3 days ago - Vertex Pharmaceuticals's Options Frenzy: What You Need to Know - Benzinga
- 6 days ago - 1.95M Reasons To Be Bullish On Vertex Pharmaceuticals Stock - Benzinga
- 6 days ago - Meet Reshma Kewalramani who joins the list of 100 Most Powerful People in Business 2025 alongside Jensen Huang, Sundar Pichai, and others - The Times of India
- 7 days ago - Vertex Pharmaceuticals Unusual Options Activity - Benzinga
- 8 days ago - 7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - The Motley Fool
- 8 days ago - Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga